43,857 Shares in Boston Scientific Corporation $BSX Purchased by Aurora Investment Counsel

Key Points

• Aurora Investment Counsel purchased 43,857 shares of Boston Scientific in the second quarter, valued at approximately $1.87 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific’s CEO and a director made significant insider purchases totaling 194,522 shares worth $9.39 million over the past three months, while the company also authorized a $5 billion share buyback.
• The company exceeded quarterly earnings and revenue expectations, reporting $0.86 EPS and $5.44 billion in revenue, up 7.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with a $71.62 average price target.

Aurora Investment Counsel bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 43,857 shares of the medical equipment provider's stock, valued at approximately $1,872,000.

A number of other institutional investors have also recently made changes to their positions in BSX. Kelleher Financial Advisors bought a new position in Boston Scientific in the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific during the first quarter valued at $28,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm's stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last three months. Company insiders own 0.34% of the company's stock.

Boston Scientific Trading Up 3.1%

BSX stock opened at $52.02 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The business has a 50 day simple moving average of $46.22 and a two-hundred day simple moving average of $58.22. The company has a market capitalization of $75.39 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same quarter in the previous year, the business posted $0.75 earnings per share. Boston Scientific's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has initiated a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent analyst reports. Needham & Company LLC dropped their price target on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating on the stock in a report on Wednesday, July 8th. Oppenheimer lowered their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an "outperform" rating on the stock in a research report on Monday, July 27th. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Argus reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Finally, Raymond James Financial reissued an "outperform" rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source